Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report)'s stock price rose 4.7% on Tuesday . The stock traded as high as $0.14 and last traded at $0.14. Approximately 4,420,182 shares traded hands during trading, a decline of 20% from the average daily volume of 5,547,915 shares. The stock had previously closed at $0.13.
Zomedica Price Performance
The stock has a market capitalization of $140.92 million, a PE ratio of -4.79 and a beta of 0.98.
Hedge Funds Weigh In On Zomedica
Several institutional investors have recently bought and sold shares of the stock. Swiss National Bank grew its holdings in Zomedica by 7.6% during the 1st quarter. Swiss National Bank now owns 2,201,200 shares of the company's stock valued at $742,000 after buying an additional 156,100 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Zomedica by 5.6% in the first quarter. BlackRock Inc. now owns 13,418,299 shares of the company's stock valued at $4,523,000 after purchasing an additional 707,993 shares in the last quarter. West Michigan Advisors LLC bought a new stake in Zomedica in the first quarter worth $28,000. UBS Group AG raised its stake in Zomedica by 207.6% during the first quarter. UBS Group AG now owns 200,000 shares of the company's stock valued at $67,000 after purchasing an additional 134,984 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Zomedica during the second quarter valued at $552,000. 8.95% of the stock is owned by hedge funds and other institutional investors.
Zomedica Company Profile
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health.
Featured Articles
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
